Top Biotechs at ASCO: Marwan Fakih on a Novel CTLA-4 Approach in MSS Colorectal Cancer
In this episode of Top Biotechs at ASCO, recorded at the ASCO 2025 Annual Meeting, Dr. Marwan Fakih, a leading medical oncologist at City of Hope, shares exciting phase 1 trial results on a novel immunotherapy strategy for microsatellite stable (MSS) colorectal cancer — a population traditionally considered resistant to immunotherapy.
Dr. Fakih presents clinical data on ADG126, a next-generation masked anti-CTLA4 antibody, combined with pembrolizumab. The study demonstrated a promising response rate of 29% at the 20 mg loading dose level in heavily pretreated MSS colorectal cancer patients. This combination not only translated deep preclinical responses into clinical benefit but also showed favorable safety, addressing long-standing toxicity concerns seen with earlier CTLA-4/PD-1 combinations.
With no high rates of therapy discontinuation due to immune-related adverse events, this regimen is now progressing into randomized trials and holds real potential to redefine treatment for MSS colorectal cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023